IL-6 Levels in Migraine Patients Receiving Topiramate

Basit Öğe Kaydı
dc.contributor.authorKoçer, Abdulkadir
dc.contributor.authorMemişoğulları, Ramazan
dc.contributor.authorDomaç, Füsun Mayda
dc.contributor.authorİlhan, Atilla
dc.contributor.authorKoçer, Emel
dc.contributor.authorOkuyucu, Şefika
dc.contributor.authorYüksel, Hatice
dc.date.accessioned2020-04-30T23:18:24Z
dc.date.available2020-04-30T23:18:24Z
dc.date.issued2009
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionKocer, Abdulkadir/0000-0003-2866-555Xen_US
dc.descriptionWOS: 000208107900007en_US
dc.descriptionPubMed: 19622115en_US
dc.description.abstractThere is considerable evidence suggesting that cytokines play important roles in pain and in mediating neurovascular inflammation associated with migraine headaches. Although consensus exists to recommend topiramate (TPM) for migraine prevention, the mechanism of action in this regard is unknown. We measured serum interleukin-6 (IL-6) levels in 66 migraine patients. Of these patients, 23 (34.9%) were taking TPM for migraine, and 43 (65.1%) were not. The IL-6 levels were compared with those of healthy controls without migraine, from the population living in the same region. The mean IL-6 levels in migraine patients taking TPM and patients who did not were 67.06 +/- 92.09 pg/mL and 44.09 +/- 59.19 pg/mL, respectively (P > 0.05). The IL-6 levels were higher in the patients taking TPM. The IL-6 level in the controls was 8.60 +/- 7.36 pg/mL, which was significantly lower than the patient group using TPM (P = 0.001). Our results show that, although IL-6 may be involved in pain induction or inflammatory mechanisms of migraine attacks, the serum IL-6 level was not reduced in migraine patients receiving TPM therapy. In conclusion, we found high IL-6 levels in migraine patients both with and without TPM therapy, suggesting that high IL-6 levels during pain-free periods could be a conditioning factor, making patients more vulnerable to pain attacks in chronic migraine. Further studies investigating the possible mechanism of TPM in migraine are needed.en_US
dc.identifier.doi10.1111/j.1533-2500.2009.00301.xen_US
dc.identifier.endpage379en_US
dc.identifier.issn1530-7085
dc.identifier.issn1533-2500
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage375en_US
dc.identifier.urihttps://doi.org/10.1111/j.1533-2500.2009.00301.x
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3276
dc.identifier.volume9en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPain Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmigraineen_US
dc.subjectinterleukin-6en_US
dc.subjecttopiramateen_US
dc.subjectpainen_US
dc.subjectinflammationen_US
dc.titleIL-6 Levels in Migraine Patients Receiving Topiramateen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
3276.pdf
Boyut:
92.04 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu